Lanicemine (AZD6765) For Treatment-Resistant Depression: NMDA Antagonist
Lanicemine (AZD6765) is an NMDA antagonist developed by the company AstraZeneca in hopes to help people with treatment-resistant depression. Let’s face it, if you have treatment-resistant depression, you are probably waiting for some sort of breakthrough in technology and/or a new class of drugs for treatment. Although many people find benefit from SSRI’s, TCA’s, and …